Immunotherapy in Chemorefractory Endometrial Cancer: Ray of Hope?
INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY(2023)
Abstract
IntroductionMolecular profiling and targeted treatment are the new approach in management of endometrial cancer.Immunotherapy has shown promising results in recurrent advanced previously treated endometrial cancer, but its role as a part of primary treatment is yet to be establised.MethodsIn this article we are reporting a case of MSI-H advanced endometrial cancer with Pembrolizumab as a third line therapy prior to attempting complete cytoreduction.ResultsAdditon of Pembrolizumab resulted in complete response to treatment in a chemorefractory advanced endometrial cancer.ConclusionsImmunotherapy is a viable novel therapeutic option to treat advanced endometrial cancer in select cases.
MoreTranslated text
Key words
Advanced endometrial cancer,Chemorefractory endometrial cancer,Immunotherapy,MSI,H endometrial cancer,Pembrolizumab
AI Read Science
Must-Reading Tree
Example
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined